{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:57:10Z","timestamp":1789084630004,"version":"build-2803163510"},"reference-count":66,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: Bone sarcomas are important contributors to early-life cancer mortality and morbidity. Optimisation of treatment regimens has improved survival, but the survival disparity between children, adolescents and young adults has widened. Population-based studies are needed to understand and address these disparities. This is the first comprehensive study of early-life bone sarcomas in Denmark.Patient\/material and methods: We combined population-wide data from national registers from 1990 to 2024 with clinical data from patient records. We calculated age-standardised incidence rates, 5-year relative survival rates stratified by several clinical factors, and Aalen-Johansen estimators for relapse\/progression and death within 5 years.Results: A total of 578 patients under 40 years of age were diagnosed with either osteosarcoma (n = 336) or Ewing sarcoma of bone (n = 242) in Denmark between 1990 and 2024. Five-year relative survival improved for patients aged 0\u201324 years but stagnated for those aged 25\u201339 years. We observed age-dependent differences in the distribution of tumours and in relative survival across anatomical sites, tumour sizes, and treatment regimens. Metastatic disease or a tumour diameter of &gt; 8 cm reduced relative survival by 19 to 45 percentage points.Interpretation: Survival disparities between children, adolescents, and young adults with bone sarcomas are likely multifactorial. Age-dependent differences in the distribution of tumours across anatomical sites and in tumour size appear to play a role. The incidence of and survival from relapse\/progression also appear to favour younger patients. Including patients in international, joint paediatric-adult treatment protocols remains a high priority.<\/jats:p>","DOI":"10.2340\/ao.v65.45405","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:50:01Z","timestamp":1776851401000},"page":"316-325","source":"Crossref","is-referenced-by-count":1,"title":["Increasing survival disparity between children, adolescents, and young adults with osteosarcoma or Ewing sarcoma of bone from 1990 to 2024: a population-based cohort study"],"prefix":"10.2340","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5039-0367","authenticated-orcid":false,"given":"Daniel Thor","family":"Halberg Dybdal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6220-9414","authenticated-orcid":false,"given":"Klaus","family":"Rostgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4436-6798","authenticated-orcid":false,"given":"Henrik","family":"Hjalgrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6859-5296","authenticated-orcid":false,"given":"Ninna","family":"Aggerholm-Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8348-9363","authenticated-orcid":false,"given":"Niels","family":"Junker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4826-8412","authenticated-orcid":false,"given":"Thomas","family":"Baad-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille Wendtland","family":"Edslev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0915-7613","authenticated-orcid":false,"given":"Eva Kristine Ruud","family":"Kj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6020-2320","authenticated-orcid":false,"given":"Akmal","family":"Safwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2324-6420","authenticated-orcid":false,"given":"Michael M\u00f8rk","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5186-3365","authenticated-orcid":false,"given":"Lisa Lyngsie","family":"Hjalgrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"151664","doi-asserted-by":"crossref","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA A Cancer J Clin. 2024;74(1):12\u201349.","DOI":"10.3322\/caac.21820"},{"key":"151665","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3322\/caac.21820","DOI":"10.3322\/caac.21820"},{"key":"151666","unstructured":"Brennan B. EURO-EWING 99: European Ewing tumour working initiative of national groups. ISRCTN Registry [Internet]. 2002 [cited 2025-Dec-15]. Available from: https:\/\/www.isrctn.com\/ISRCTN61438620"},{"key":"151667","doi-asserted-by":"crossref","unstructured":"Whelan J, Le Deley MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N, et al. High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: results of Euro-E.W.I.N.G.99 and Ewing-2008. JCO. 2018;36(31):3110\u20139.","DOI":"10.1200\/JCO.2018.78.2516"},{"key":"151668","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2018.78.2516","DOI":"10.1200\/JCO.2018.78.2516"},{"key":"151669","doi-asserted-by":"crossref","unstructured":"Anderton J, Moroz V, Marec-B\u00e9rard P, Gaspar N, Laurence V, Mart\u00edn-Broto J, et al. International randomised controlled trial for the treatment of newly diagnosed Ewing sarcoma family of tumours \u2013 EURO EWING 2012 Protocol. Trials. 2020;21(1):96.","DOI":"10.1186\/s13063-019-4026-8"},{"key":"151670","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s13063-019-4026-8","DOI":"10.1186\/s13063-019-4026-8"},{"key":"151671","doi-asserted-by":"crossref","unstructured":"Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol. 2015;26(2):407\u201314.","DOI":"10.1093\/annonc\/mdu526"},{"key":"151672","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdu526","DOI":"10.1093\/annonc\/mdu526"},{"key":"151673","doi-asserted-by":"crossref","unstructured":"Khan M, Brennan B. International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma \u2013 trial 1 (INTER-EWING-1). ISRCTN Registry [Internet]. 2023 [cited 2025-Dec-15]. Available from: https:\/\/www.isrctn.com\/ISRCTN17938906","DOI":"10.1186\/ISRCTN17938906"},{"key":"151674","unstructured":"German Paediatric Oncology Group. International Euro ewing trial for treatment optimisation in patients with ewing sarcoma [Internet]. EU Clinical Trials Register; 2021 [cited 2025-Dec-15]. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004153-93\/DE"},{"key":"151675","unstructured":"McCabe M. Chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma [Internet]. [cited 2026 Jan 14]. Available from: http:\/\/www.isrctn.com\/ISRCTN36453794"},{"key":"151676","doi-asserted-by":"crossref","unstructured":"Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment \u2013 where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523\u201332.","DOI":"10.1016\/j.ctrv.2013.11.006"},{"key":"151677","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ctrv.2013.11.006","DOI":"10.1016\/j.ctrv.2013.11.006"},{"key":"151678","doi-asserted-by":"crossref","unstructured":"Potratz J, Dirksen U, J\u00fcrgens H, Craft A. Ewing sarcoma: clinical state-of-the-art. Pediatr Hematol Oncol. 2012;29(1):1\u201311.","DOI":"10.3109\/08880018.2011.622034"},{"key":"151679","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3109\/08880018.2011.622034","DOI":"10.3109\/08880018.2011.622034"},{"key":"151680","doi-asserted-by":"crossref","unstructured":"Rainusso N, Wang LL, Yustein JT. The Adolescent and young adult with cancer: state of the art \u2013 bone tumors. Curr Oncol Rep. 2013;15(4):296\u2013307.","DOI":"10.1007\/s11912-013-0321-9"},{"key":"151681","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s11912-013-0321-9","DOI":"10.1007\/s11912-013-0321-9"},{"key":"151682","doi-asserted-by":"crossref","unstructured":"Chen I, Pasalic D, Fischer-Valuck B, Frangoul H, DeWees T, Shinohara ET, et al. Disparity in outcomes for adolescent and young adult patients diagnosed with pediatric solid tumors across 4 decades. Am J Clin Oncol. 2018;41(5):471\u20135.","DOI":"10.1097\/COC.0000000000000304"},{"key":"151683","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/COC.0000000000000304","DOI":"10.1097\/COC.0000000000000304"},{"key":"151684","doi-asserted-by":"crossref","unstructured":"Tirtei E, Michelsen SW, Haveman LM, Meazza C, Oliveira JF, Rasool A, et al. Prognostic factors in newly diagnosed high\u2010grade osteosarcoma \u2013 a systematic review. Cancer Med. 2025;14(14):e71044.","DOI":"10.1002\/cam4.71044"},{"key":"151685","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cam4.71044","DOI":"10.1002\/cam4.71044"},{"key":"151686","doi-asserted-by":"crossref","unstructured":"Trama A, Lasalvia P, Stark D, McCabe MG, Van Der Graaf W, Gaspar N, et al. Incidence and survival of European adolescents and young adults diagnosed with sarcomas: EUROCARE-6 results. Eur J Cancer. 2025;217:115212.","DOI":"10.1016\/j.ejca.2024.115212"},{"key":"151687","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115212","DOI":"10.1016\/j.ejca.2024.115212"},{"key":"151688","doi-asserted-by":"crossref","unstructured":"Schulpen M, Haveman LM, Van Der Heijden L, Kaal SEJ, Bramer JAM, Fajardo RD, et al. The survival disparity between children and adolescents and young adults (AYAs) with Ewing sarcoma in the Netherlands did not change since the 1990s despite improved survival: a population-based study. Eur J Cancer. 2024;208:114209.","DOI":"10.1016\/j.ejca.2024.114209"},{"key":"151689","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114209","DOI":"10.1016\/j.ejca.2024.114209"},{"key":"151690","doi-asserted-by":"crossref","unstructured":"Zeckanovic A, Fuchs P, Heesen P, Bodmer N, Otth M, Scheinemann K. Pediatric-inspired regimens in the treatment of acute lymphoblastic leukemia in adolescents and young adults: a systematic review. Curr Oncol. 2023;30(9):8612\u201332.","DOI":"10.3390\/curroncol30090625"},{"key":"151691","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/curroncol30090625","DOI":"10.3390\/curroncol30090625"},{"key":"151692","doi-asserted-by":"crossref","unstructured":"Toft N, Birgens H, Abrahamsson J, Gri\u0161kevi\u010dius L, Hallb\u00f6\u00f6k H, Heyman M, et al. Results of NOPHO ALL2008 treatment for patients aged 1\u201345 years with acute lymphoblastic leukemia. Leukemia. 2018;32(3):","DOI":"10.1038\/leu.2017.265"},{"key":"151693","unstructured":"606\u201315."},{"key":"151694","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/leu.2017.265","DOI":"10.1038\/leu.2017.265"},{"key":"151695","unstructured":"Bishop MW. A feasibility and randomized Phase II\/III study of the VEGFR2\/MET inhibitor cabozantinib in combination with cytotoxic chemotherapy for newly diagnosed osteosarcoma. ClinicalTrials.gov [Internet]. 2025 [cited 2025-Dec-15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05691478"},{"key":"151696","doi-asserted-by":"crossref","unstructured":"Schmidt M, Schmidt SAJ, Adelborg K, Sundb\u00f8ll J, Laugesen K, Ehrenstein V, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563\u201391.","DOI":"10.2147\/CLEP.S179083"},{"key":"151697","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CLEP.S179083","DOI":"10.2147\/CLEP.S179083"},{"key":"151698","unstructured":"World Health Organization. International classification of diseases for oncology. 3rd Edition, 2nd update (ICD-O-3.2) [Internet]. WHO; 2019 [cited 2025 Apr 23]. Available from: https:\/\/www.who.int\/standards\/classifications\/other-classifications\/international-"},{"key":"151699","unstructured":"classification-of-diseases-for-oncology"},{"key":"151700","unstructured":"National Cancer Institute. Adolescents and young adults with cancer [Internet]. 2024 [cited 2025 Dec 17]. Available from: https:\/\/www.cancer.gov\/types\/aya"},{"key":"151701","unstructured":"Mountzios G, Bielack SS, Mehra N. ESMO handbook of cancer in"},{"key":"151702","unstructured":"adolescents and young adults. Mountzios G, Bielack SS, Mehra N, editors. Lugano. European Society for Medical Oncology; 2022."},{"key":"151703","doi-asserted-by":"crossref","unstructured":"Bosma SE, Ayu O, Fiocco M, Gelderblom H, Dijkstra PDS. Prognostic factors for survival in Ewing sarcoma: a systematic review. Surg Oncol. 2018;27(4):603\u201310.","DOI":"10.1016\/j.suronc.2018.07.016"},{"key":"151704","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.suronc.2018.07.016","DOI":"10.1016\/j.suronc.2018.07.016"},{"key":"151705","doi-asserted-by":"crossref","unstructured":"Schroeder H, Rechnitzer C, Wehner P, Rosth\u00f8j S, M\u00f8ller JK, Lausen B, et al. Danish Childhood Cancer Registry. CLEP. 2016;8:461\u20134.","DOI":"10.2147\/CLEP.S99508"},{"key":"151706","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CLEP.S99508","DOI":"10.2147\/CLEP.S99508"},{"key":"151707","doi-asserted-by":"crossref","unstructured":"Jorgensen P, Lausten G, Becic Pedersen A. The Danish Sarcoma Database. CLEP. 2016;8:685\u201390.","DOI":"10.2147\/CLEP.S99495"},{"key":"151708","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CLEP.S99495","DOI":"10.2147\/CLEP.S99495"},{"key":"151709","doi-asserted-by":"crossref","unstructured":"Dickman PW, Coviello E. Estimating and modeling relative survival. Stata J. 2015;15(1):186\u2013215.","DOI":"10.1177\/1536867X1501500112"},{"key":"151710","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/1536867X1501500112","DOI":"10.1177\/1536867X1501500112"},{"key":"151711","doi-asserted-by":"crossref","unstructured":"Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26(11):2389\u2013430.","DOI":"10.1002\/sim.2712"},{"key":"151712","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/sim.2712","DOI":"10.1002\/sim.2712"},{"key":"151713","doi-asserted-by":"crossref","unstructured":"Williams LA, Barragan S, Lu Z, Weigel BJ, Spector LG. Sex differences in osteosarcoma survival across the age spectrum: a National Cancer Database analysis (2004\u20132016). Cancer Epidemiol. 2024;92:102565.","DOI":"10.1016\/j.canep.2024.102565"},{"key":"151714","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.canep.2024.102565","DOI":"10.1016\/j.canep.2024.102565"},{"key":"151715","doi-asserted-by":"crossref","unstructured":"Dybdal DTH, Davidsson \u00d3B, S\u00f8egaard SH, Petersen MM, Aggerholm-Pedersen N, Hjalgrim H, et al. Use of healthcare services and prescription medication prior to sarcoma diagnosis in children, adolescents, and young adults in 1997\u20132020: a population-based cohort study. Cancer Causes Control. 2025;36(12):1963\u201373.","DOI":"10.1007\/s10552-025-02077-1"},{"key":"151716","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10552-025-02077-1","DOI":"10.1007\/s10552-025-02077-1"},{"key":"151717","doi-asserted-by":"crossref","unstructured":"Paioli A, Luksch R, Fagioli F, Tamburini A, Cesari M, Palmerini E, et al. Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age. J Chemother. 2014;26(1):49\u201356.","DOI":"10.1179\/1973947813Y.0000000103"},{"key":"151718","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1179\/1973947813Y.0000000103","DOI":"10.1179\/1973947813Y.0000000103"},{"key":"151719","doi-asserted-by":"crossref","unstructured":"Mills LJ, Spector LG, Largaespada DA, Williams LA. Sex differences in expression of immune elements emerge in children, young adults and mice with osteosarcoma. Biol Sex Differ. 2021;12(1):5.","DOI":"10.1186\/s13293-020-00347-y"},{"key":"151720","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s13293-020-00347-y","DOI":"10.1186\/s13293-020-00347-y"},{"key":"151721","doi-asserted-by":"crossref","unstructured":"Gusho CA, Weiss MC, Lee L, Gitelis S, Blank AT, Wang D, et al. The clinical utility of next-generation sequencing for bone and soft tissue sarcoma. Acta Oncol. 2022;61(1):38\u201344.","DOI":"10.1080\/0284186X.2021.1992009"},{"key":"151722","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2021.1992009","DOI":"10.1080\/0284186X.2021.1992009"},{"key":"151723","doi-asserted-by":"crossref","unstructured":"Fernandes JS, Blattmann C, Hecker-Nolting S, Kager L, Kevric M, Mettmann V, et al. Beyond 5-year survival. A report from the Cooperative Osteosarcoma Study Group (COSS). Cancer Med. 2024;13(1):e6893.","DOI":"10.1002\/cam4.6893"},{"key":"151724","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cam4.6893","DOI":"10.1002\/cam4.6893"},{"key":"151725","doi-asserted-by":"crossref","unstructured":"Bielack S, J\u00fcrgens H, Jundt G, Kevric M, K\u00fchne T, Reichardt P, et al. Osteosarcoma: the COSS experience. Cancer Treat Res. 2009;152:","DOI":"10.1007\/978-1-4419-0284-9_15"},{"key":"151726","unstructured":"289\u2013308."},{"key":"151727","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/978-1-4419-0284-9_15","DOI":"10.1007\/978-1-4419-0284-9_15"},{"key":"151728","doi-asserted-by":"crossref","unstructured":"Smith MA, Joffe S. Will my child do better if she enrolls in a clinical trial? Cancer. 2018;124(20):3965\u20138.","DOI":"10.1002\/cncr.31722"},{"key":"151729","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cncr.31722","DOI":"10.1002\/cncr.31722"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45405\/53620","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45405\/53620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:50:42Z","timestamp":1776851442000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/45405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":66,"URL":"https:\/\/doi.org\/10.2340\/ao.v65.45405","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]}}}